Thông tin thuốc gốc
Chỉ định và Liều dùng
Congestive heart failure post-myocardial infarction
Adult: Initially, 25 mg once daily, titrate to 50 mg once daily w/in 4 wk if tolerated. Dose adjustment based on serum K level: <5 mEq/L: Increase 25 mg every other day to 25 mg daily or 25 mg daily to 50 mg daily. 5-5.4 mEq/L: No dosage adjustment. 5.5-5.9 mEq/L: Decrease from 50 mg daily to 25 mg daily, or 25 mg daily to 25 mg every other day, or 25 mg every other day to withhold therapy. ≥6 mEq/L: Withhold therapy; restart at 25 mg every other day when K level falls to <5.5 mEq/L.

Adult: As monotherapy or in combination w/ other antihypertensives. Initially, 50 mg daily. Max: 50 mg bid.
Nhóm bệnh nhân đặc biệt
Patient on mild to moderate CYP3A4 inhibitors: Max: 25 mg once daily.
Suy thận
CrCl (mL/min) Dosage
≤50 Avoid use.
Congestive Heart Failute Post-Myocardial Infarction:
CrCl (mL/min) Dosage
<30 Avoid use.
30-60 Initially, 25 mg on alternate days.
Cách dùng
May be taken with or without food.
Chống chỉ định
CrCl <30 mL/min. Concomitant use w/ potent CYP3A4 inhibitors. Patient treated for HTN: Type 2 DM w/ microalbuminuria. CrCl ≤50 mL/min. Concomitant use w/ K-sparing diuretics or K supplements.
Thận trọng
Diabetic patient w/ CHF post-MI. Renal and severe hepatic impairment. Pregnancy and lactation.
Tác dụng không mong muốn
Hyperkalaemia, urinary tract disorders, CNS and GI disturbances, dizziness, fatigue, flu-like symptoms, cough, diarrhoea, abdominal pain, decreased serum Na concentrations, increased serum creatinine concentrations, abnormal vag bleeding, gynaecomastia, hypercholesterolemia, hypertriglyceridemia, mastodynia, or albuminuria.
Chỉ số theo dõi
Monitor BP, serum K levels (prior to treatment, w/in the 1st wk and periodically thereafter).
Quá liều
Symptoms: Hyperkalaemia, hypotension. Management: Symptomatic and supportive treatment. Admin activated charcoal. Initiate standard therapy for hyperkalaemia.
Tương tác
May increase risk of hyperkalaemia w/ ACE inhibitors and/or angiotension receptor blocker, ciclosporin, tacrolimus, trimethoprim. May reduce antihypertensive effect w/ NSAIDs, glucocorticoids, tetracosactide. May enhance hypotensive effect of α1-blockers (e.g. alfuzosin, prazosin), TCAs, amifostine, baclofen, neuroleptics. May increase plasma level w/ mild to moderate CYP3A4 inhibitors (e.g. fluconazole, erythromycin, saquinavir, amiodarone, diltiazem, verapamil).
Potentially Fatal: Significantly increased plasma level w/ potent CYP3A4 inhibitors (e.g. itraconazole, nefazodone, clarithromycin, telithromycin, ketoconazole, nelfinavir, ritonavir). May enhance hyperkalaemic effect of K-sparing diuretics or K supplements in patients w/ HTN.
Tương tác với thức ăn
May reduce serum level w/ St John's wort. May increase serum level w/ grapefruit juice.
Tác dụng
Description: Eplerenone selectively binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a key component in the renin-angiotensin-aldosterone-system, which is involved in the regulation of BP and pathophysiology of CV disease. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g. kidney, GI tract) and nonepithelial (e.g. heart, blood vessels, brain) tissues; causing increases in BP by inducing Na reabsorption, vascular remodelling, water retention, endothelial dysfunction and possibly other mechanisms.
Absorption: Bioavailability: 69%. Time to peak plasma concentration: Approx 1.5 hr.
Distribution: Volume of distribution: 43-90 L. Plasma protein binding: Approx 50% (primarily to α1-acid glycoprotein).
Metabolism: Primarily hepatic by CYP3A4 isoenzyme to inactive metabolites.
Excretion: Via urine (approx 67%); faeces (32%); <5% as unchanged drug in the urine and faeces. Elimination half-life: Approx 4-6 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Eplerenone, CID=443872, https://pubchem.ncbi.nlm.nih.gov/compound/Eplerenone (accessed on Jan. 22, 2020)

Bảo quản
Store at 25°C.
Phân loại MIMS
Thuốc lợi tiểu
Tài liệu tham khảo
Anon. Eplerenone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/11/2014.

Buckingham R (ed). Eplerenone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2014.

Eplerenone tablet (Apotex Corp). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 11/11/2014.

Inspra Tablets. U.S. FDA. https://www.fda.gov/. Accessed 11/11/2014.

Joint Formulary Committee. Eplerenone. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Eplerenone. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 11/11/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Eplerenone từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in